Possible explanations for this effect may also involve the stage of the disease (CML in advanced phase) and the higher number of CD34+ (median 5.4 × 106/kg bw) used in our cohort as compared to the previously published results. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.